Patent · US Active

KRAS G12C inhibitors and methods of using the same

US11053226B2 · kind B2 · utility

21Cited by

45References

48Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Youngsook Shin · Emeryville, US
Victor J. Cee · Thousand Oaks, US
Christopher M. Tegley · Thousand Oaks, US
Brian Alan LANMAN · Calabasas, US
Ryan Wurz · Newbury Park, US
Kevin Yang · San Gabriel, US
Vu Van Ma · Simi Valley, US
Daniel Erlanson · San Francisco, US
Joon Won Jeong · Belmont, US
Raymond V. Fucini · San Bruno, US
Jeffrey Iwig · Albany, US

Key dates

Filing date	Nov 18, 2019
Grant date	Jul 6, 2021
Priority date	—
Expiry date	Dec 11, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.